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Voluntary sector organizations in the UK have an enviable and
successful track record in influencing health care for people
affected by breast cancer, and it is entirely refutable that they
in any way distort (that is, misrepresent) the cancer budget
unfairly in favour of breast cancer.
Investment in terms of cancer budgets will inevitably always
be somewhat biased toward the most significant health
problems, and probably justifiably so. Breast cancer has the
highest incidence of any cancer in the UK, with more than
44,000 new cases diagnosed each year [1]. The same goes
for its prevalence. At any one time in the UK there are an
estimated 172,000 people living with breast cancer, as
compared with 77,000 with colorectal cancer, 32,000 with
lung cancer and 31,000 with melanoma. Thus, if breast
cancer attracts a higher proportion of expenditure, then
arguably this represents logical health economics relative to
the scale of the problem. The significance and prevalence of
breast cancer as a major health problem within the UK is also
reflected in government targets and plans, which commonly
cite breast cancer as a priority area [2].
Mortality rates from breast cancer are improving and have
fallen by more than 30% in recent years [1]. Breast cancer is
no longer the biggest cancer killer in the UK, but it is also not
alone in terms of such improvement. Testicular cancer
mortality rates have also fallen by approximately 30% and
colorectal cancer mortality is down by 18% [1]. It is highly
questionable to suggest that reductions in breast cancer
mortality result from a disproportionate slice of the cancer
budget when mortality is also improving in clinical areas
alleged not to have benefited from this so-called distortion.
A key influence in allocation of cancer drug budgets is the
perceived efficacy of those drugs. Distortion, or misrepre-
sentation, of the cancer drug budget by voluntary sector
organizations, or whoever, would suggest other cancer drugs
receive less funding regardless of efficacy. However, efficacy
is determined by formal bodies (for example, the National
Institute of Health and Clinical Excellence and the Scottish
Medicines Consortium) and not by voluntary sector groups.
Interestingly, a review of National Institute of Health and
Clinical Excellence (NICE) appraisals within cancer reveals
an equivalent number of reviews for breast and gastro-
intestinal cancers, with lung and urogenital cancer close
behind [3].
The emerging pressure to ensure fast and favourable
appraisals has been evident within the UK, and access to
trastuzumab is a pertinent recent example. In this case,
however, the key players equally responsible for instigating
change were as much the high profile legal battles that
patients engaged in, the incitement and repeated calls of
injustice by the media, and thinly disguised political gaming.
Voluntary sector organizations played a role too, but in
ensuring equity and speeding up access, not in distorting
cancer budgets. Cancer charities have been rightly vocal in
criticizing the interval between creation of a new drug, release
of data, licence application and formal approval. Cancer
charities have also rightly called for funding to accompany
approved drugs, concerned that no new money is attached to
facilitate implementation after positive appraisals.
Importantly, voluntary sector organizations have been visible
and assertive in condemning the postcode lottery within
cancer care and specifically unequal access to new drugs.
Their message was not one that, for example, merely
demanded access to trastuzumab for all, but rather was one
of socially responsible campaigning that deemed the vast
geographical variations in access to both HER2 testing and
receipt of the drug in different areas of the UK as unethical
and unacceptable. It was for similar reasons that they were
also instrumental in making public the fact that aromatase
inhibitors were approved in Scotland a whole year before
they were in England. It is also why these organizations called
for a national audit of uptake of NICE guidance to be
published annually, in order to put an end to wildly inequitable
and all too variable spending on cancer drugs and response
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times to implementation of appraisal findings by Primary Care
Trusts.
It is important to think beyond the obvious consideration of
drug expenditure when exploring the cancer budget,
otherwise there is a danger of selling short the bigger picture.
For example, within lung cancer expenditure a major focus
has been on prevention, not least because lung cancer has a
far greater potential for primary prevention. Considerable
funds have been devoted to smoking cessation campaigns
over the past 10 years, regrettably with uncertain efficacy
because female incidence and overall mortality rates from
lung cancer have both increased [1]. In addition, drug costs
represent only about 10% of total cancer spending, meaning
there are many other areas of inequity and a worrying
prediction of a massive future short fall [4]. Breast cancer
groups have led highly visible campaigns on, for example,
adjuvant radiotherapy waiting times and excessive delays for
patients referred as nonurgent to be assessed.
Probably, teamwork, collaboration and strength in numbers
will strengthen campaigning in the future. There is now a
coalition of 34 UK cancer charities of differing sizes and
remits whose jointly produced white paper [5] calls for
efficient distribution of resources and reducing postcode and
pan-European inequalities, because every person deserves
high quality cancer care and treatment regardless of location,
sex, age, ethnicity, financial status, or type of cancer.
One public misconception about cancer spending that is
worthy of correction is the belief that cancer care gets the
majority share of the health budget overall. In fact, an analysis
of the total amount spent on different diseases by Primary
Care Trusts provides a top-level view of the way in which the
majority of the National Health Service (NHS) budget is spent
and reveals that in 2004 to 2005 twice as much was spent
on mental health services than on cancer care. This could be
said to reflect decisions about the priorities that the NHS
gives to different services [6].
It would certainly be ludicrous (not to mention a waste of
valuable time and resources) for breast cancer voluntary
organizations or clinicians to feel apologetic for the
improvements in breast cancer treatment and survival, just
because not all cancers have benefited to the same extent.
Breast cancer charities have been enviably successful at
campaigning, influencing health policy and keeping breast
cancer at the top of the agenda. As such, their model should
be presented as one that other cancers groups can learn
from, follow and hopefully reap the rewards from too.
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